Exploration of 1,2,3‐triazolo fused triterpenoids as inhibitors of human coronavirus 229E targeting the viral nsp15 protein

Abstract

AbstractThe coronavirus disease‐19 (COVID‐19) pandemic has raised major interest in innovative drug concepts to suppress human coronavirus (HCoV) infections. We previously reported on a class of 1,2,3‐triazolo fused betulonic acid derivatives causing strong inhibition of HCoV‐229E replication via the viral nsp15 protein, which is proposedly related to compound binding at an intermonomer interface in hexameric nsp15. In the present study, we further explored the structure–activity relationship (SAR), by varying the substituent at the 1,2,3‐triazolo ring as well as the triterpenoid skeleton. The 1,2,3‐triazolo fused triterpenoids were synthesized by a multicomponent triazolization reaction, which has been developed in‐house. Several analogs possessing a betulin, oleanolic acid, or ursolic acid core displayed favorable activity and selectivity (EC50 values for HCoV‐229E: 1.6–3.5 μM), but neither of them proved as effective as the lead compound containing betulonic acid. The 18β‐glycyrrhetinic acid‐containing analogs had low selectivity. The antiviral findings were rationalized by in silico docking in the available structure of the HCoV‐229E nsp15 protein. The new SAR insights will aid the further development of these 1,2,3‐triazolo fused triterpenoid compounds as a unique type of coronavirus inhibitors.